WallStreetZenWallStreetZen

NASDAQ: GYRE
Gyre Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their GYRE stock forecasts and price targets.

Forecast return on equity

Is GYRE forecast to generate an efficient return?

Company
70.61%
Industry
29.99%
Market
177.22%
GYRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GYRE forecast to generate an efficient return on assets?

Company
38.25%
Industry
20.46%
GYRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GYRE earnings per share forecast

What is GYRE's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.24
Avg 3 year Forecast
$1.80

GYRE revenue forecast

What is GYRE's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$111.7M-6.44%
Avg 2 year Forecast
$142.4M+19.27%
Avg 3 year Forecast
$445.0M+272.78%
GYRE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GYRE revenue growth forecast

How is GYRE forecast to perform vs Biotechnology companies and vs the US market?

Company
13.18%
Industry
29.47%
Market
11.99%
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GYRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GYRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GYRE$4.44N/AN/A
OCS$7.28$35.83+392.21%Strong Buy
YDES$6.95N/AN/A
MNPR$72.81$130.50+79.23%Strong Buy
ARVN$7.42$15.88+113.95%Strong Buy
View Top Biotech Stocks

Gyre Therapeutics Stock Forecast FAQ

What is GYRE's earnings growth forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.18%.

Gyre Therapeutics's earnings in 2026 is -$18,467,000.On average, 5 Wall Street analysts forecast GYRE's earnings for 2026 to be -$47,202,119, with the lowest GYRE earnings forecast at -$66,660,588, and the highest GYRE earnings forecast at -$25,758,775. On average, 4 Wall Street analysts forecast GYRE's earnings for 2027 to be -$26,728,911, with the lowest GYRE earnings forecast at -$51,361,436, and the highest GYRE earnings forecast at $0.

In 2028, GYRE is forecast to generate $200,182,481 in earnings, with the lowest earnings forecast at $192,332,188 and the highest earnings forecast at $206,070,201.

If you're new to stock investing, here's how to buy Gyre Therapeutics stock.

What is GYRE's revenue growth forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's forecast annual revenue growth rate of 13.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.3%.

Gyre Therapeutics's revenue in 2026 is $119,383,000.On average, 5 Wall Street analysts forecast GYRE's revenue for 2026 to be $12,454,535,035, with the lowest GYRE revenue forecast at $11,900,331,085, and the highest GYRE revenue forecast at $12,879,387,560. On average, 4 Wall Street analysts forecast GYRE's revenue for 2027 to be $15,877,887,399, with the lowest GYRE revenue forecast at $13,113,558,242, and the highest GYRE revenue forecast at $18,639,986,359.

In 2028, GYRE is forecast to generate $49,625,228,100 in revenue, with the lowest revenue forecast at $47,678,266,137 and the highest revenue forecast at $51,084,892,024.

What is GYRE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GYRE) forecast ROA is 38.25%, which is higher than the forecast US Biotechnology industry average of 20.43%.

What is GYRE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GYRE) Gyre Therapeutics's current Earnings Per Share (EPS) is -$0.20. On average, analysts forecast that GYRE's EPS will be -$0.42 for 2026, with the lowest EPS forecast at -$0.60, and the highest EPS forecast at -$0.23. On average, analysts forecast that GYRE's EPS will be -$0.24 for 2027, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at $0.00. In 2028, GYRE's EPS is forecast to hit $1.80 (min: $1.72, max: $1.85).

What is GYRE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GYRE) forecast ROE is 70.61%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.